Table 4.
Cost per patient of management of the adverse events (AEs) according to the Monte Carlo simulation
AE severity | Erlotinib | Afatinib | Difference (95% CI)* |
---|---|---|---|
AE grade ≤2 | €550.86 | €980.63 | €−429.76 (€−292.48 to −536.40) |
AE grade ≥3 | €106.58 | €291.52 | €−184.95 (€−50.08 to −344.89) |
All AEs | €657.44 | €1,272.15 | €−614.71 (€−342.57 to −881.29) |
Note:
The negative values indicate savings with erlotinib versus afatinib.
Abbreviation: CI, confidence interval.